Stock INDP INDAPTUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Delayed Nasdaq
Other stock markets
 15:22:50 30/04/2024 BST 		5-day change 1st Jan Change
2.227 USD +4.96% Intraday chart for Indaptus Therapeutics, Inc. -11.85% +24.72%
03-14 Top Premarket Gainers MT
03-13 Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Midday Gainers
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20
Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
Indaptus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Indaptus Therapeutics, Inc. Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at American Association for Cancer Research Conference 2023
Indaptus Therapeutics, Inc. Announces Executive Changes
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Indaptus Therapeutics, Inc. Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
Indaptus Therapeutics, Inc. Doses First Subject in Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INDP Stock
  4. News Indaptus Therapeutics, Inc.
  5. Other languages